Literature DB >> 15978106

Determinants of the APTT- and ETP-based APC sensitivity tests.

M C H de Visser1, A van Hylckama Vlieg, G Tans, J Rosing, A E A Dahm, P M Sandset, F R Rosendaal, R M Bertina.   

Abstract

BACKGROUND: A reduced sensitivity for activated protein C (APC) is associated with an increased risk of venous thrombosis even in the absence of the factor (F)V Leiden mutation. This risk has been demonstrated with two APC sensitivity tests, which quantify the effects of APC on the activated partial thromboplastin time (APTT) and the endogenous thrombin potential (ETP), respectively.
OBJECTIVES: We examined determinants of both APC sensitivity tests in the control group of the Leiden Thrombophilia Study (LETS).
METHODS: Multiple linear regression analysis was performed with normalized APC-SR(APTT) or APC-SR(ETP) as dependent variable and putative determinants [levels of FII, FV, FVII, FVIII, FIX, FX, FXI, FXII, FXIII A subunit, FXIII B subunit, protein S total, protein S free, protein C, tissue factor pathway inhibitor (TFPI) total, TFPI free, antithrombin and fibrinogen] as independent variables. RESULTS AND
CONCLUSIONS: The major determinant of the APTT-based test was FVIII level, followed by FII level. The ETP-based test was influenced most by free protein S and free TFPI levels. In both tests FXa formation plays a major role, as the effect of FVIII and TFPI on the tests seems to be executed via FXa. The ETP-based test was also strongly influenced by oral contraceptive use, even when we adjusted for all the clotting factors listed above. This means that the effect of oral contraceptives on the ETP-based test is not fully explained by the changes of coagulation factor levels investigated in this study, and that the molecular basis of acquired APC resistance during use of oral contraceptives remains to be established.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15978106     DOI: 10.1111/j.1538-7836.2005.01430.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.

Authors:  Pansakorn Tanratana; Paul Ellery; Pamela Westmark; Alan E Mast; John P Sheehan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-02       Impact factor: 8.311

2.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

3.  Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.

Authors:  Heiko Rühl; Lars Schröder; Jens Müller; Shorena Sukhitashvili; Julia Welz; Walther C Kuhn; Johannes Oldenburg; Christian Rudlowski; Bernd Pötzsch
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

4.  Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation.

Authors:  M Ibrahim-Kosta; P Suchon; F Couturaud; D Smadja; R Olaso; M Germain; N Saut; L Goumidi; C Derbois; F Thibord; S Debette; P Amouyel; J F Deleuze; P van Doorn; E Castoldi; E Patin; M C Alessi; D A Trégouët; P E Morange
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

5.  The influence of corn trypsin inhibitor on the contribution of coagulation determinants to the Technoclone Thrombin Generation Assay (TGA) and the Calibrated Automated Thrombogram (CAT).

Authors:  Carolina E Touw; Ype de Jong; Astrid van Hylckama Vlieg
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

6.  Analytical performance of the endogenous thrombin potential-based activated protein C resistance assay on the automated ST Genesia system.

Authors:  Laure Morimont; Charline Leclercq; Marie Didembourg; Émilie De Gottal; Audrey Carlo; Ulysse Gaspard; Jean-Michel Dogné; Jonathan Douxfils
Journal:  Res Pract Thromb Haemost       Date:  2022-04-07

7.  A Case of Oral-contraceptive Related Ischemic Colitis in Young Woman.

Authors:  Choon Sik Seon; Young Sook Park; Se Hwan Park; Sang Ryol Ryu; Yun Ju Jo; Seong Hwan Kim; Byoung Kwan Son; Sang Bong Ahn
Journal:  Clin Endosc       Date:  2011-12-31

Review 8.  Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.

Authors:  Laure Morimont; Hélène Haguet; Jean-Michel Dogné; Ulysse Gaspard; Jonathan Douxfils
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.